Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tamuzimod
- Development stage
- Phase 2
- Lead developer
- Ventyx Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tamuzimod is an orally bioavailable small molecule that acts as a highly selective modulator of sphingosine-1-phosphate receptor subtype 1 (S1PR1). It is being developed for the treatment of moderately to severely active ulcerative colitis. In phase 2 trials, tamuzimod demonstrated high rates of clinical and endoscopic remission at both 13 and 52 weeks and a favorable safety profile compared to other oral options for ulcerative colitis therapy. Mechanistically, tamuzimod limits the egress of lymphocytes from lymph nodes, decreasing their infiltration into inflamed tissues and thereby reducing chronic intestinal inflammation. It is not currently approved and is being developed by Ventyx Biosciences and was originally discovered by Oppilan Pharma[1][2][3][4][7][9].
- Brand names
- tamuzimod
- Other names
- tamuzimodtamuzimod [INN]Tamuzimod (USAN/INN)TAMUZIMOD [USAN]tamuzimod acetate
02
Targets
EDG1 (Sphingosine-1-phosphate receptors)
Beyond the preview
Go deeper on tamuzimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tamuzimod.